|
1.Date of occurrence of the event:2020/04/16
2.Company name:Chunghwa Chemical Synthesis & Biotech Co.,Ltd.
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):Head office
4.Reciprocal shareholding ratios:N/A
5.Name of the reporting media:Economic Daily News、Liberty Times Net、
Infotimes、www.investor.com.tw、breaknews
6.Content of the report:
” In terms of the preliminary clinical report of Remdesivir showing
promising result towards to the treatment of COVID-19 patients with
severe symptoms, CCSB (Chunghwa Chemical Synthesis & Biotech Co. Ltd.),
one of the biggest API manufactures in Taiwan, announced on Apr 15th
that the development of the lab scale batch has been successfully
completed. Three batches of Remdesivir has been produced with purity
99.72% in lab and obtained 4.73 g in total (1.60 g, 1.55 g, and 1.58 g,
respectively).
CCSB and CCPC (China Chemical & Pharmaceutical Co., Ltd.) will devote
our efforts and capabilities to the mass production of Remdesivir as
soon as the government calls for our instant assistance and supports.
7.Cause of occurrence:
CCSB participated the project of Taiwan FDA, Influenza Vaccine
Production Process Improvement Project in 2007, and successfully
delivered 40kg Tamiflu API on time. Based on the successful
experience, CCSB focuses on the production research of Remdesivir to
implement CSR when people all over the world have being suffering from
the outbreak of COVID-19 since February 2020.
8.Countermeasures:
CCSB already completed the laboratory process of Remdesivir, proving
that CCSB has the ability of development.
Remdesivir hasn't been launched officially in the market yet as well
as in the originator's clinical stage.
CCSB does not plan the launch time of Remdesivir now but will wait
for the clinical results.
CCSB will fully cooperate and support to government's policies, that
won't cause any significant impact on our finances and sales.
9.Any other matters that need to be specified:
New product development completion date:
lab scale manufacturing method has been completed on 04/14/2020.
New product information:
CCSB has synthesized 3 lots of Remdesivir, a total of 4.73 grams
with 99.72% purity.
Impact on company finance and business:
That won't cause any significant impact on our finances and sales.
|
